Early propylactic factor replacement therapy can prevent chronic complications of severe hemophilia such as arthropathy. With prophylaxis life expectancy is close to normal and the quality of life as well.
A report from the CDC in the USA reports a rare case of transmission of HIV with blood transfusion. This rare event which is estimated to occur at the frequency of 1 in 1,500,000 procedures. It is a sobering reminder to the hemophilia community that all safety precautions are necessary during production of factor concentrates. It also supports the view that recombinant factor concentrates may be preferable to plasma derived products from the infectious disease point of view.